These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35450052)

  • 1. Single Dose Comparative Bioavailability Study of Lisdexamfetamine Dimesylate as Oral Solution Versus Reference Hard Capsules in Healthy Volunteers.
    Rizea-Savu S; Duna SN; Panagiotopoulos D; Sandulovici RC
    Front Pharmacol; 2022; 13():881198. PubMed ID: 35450052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
    Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
    CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.
    Najib J; Wimer D; Zeng J; Lam KW; Romanyak N; Paige Morgan E; Thadavila A
    J Cent Nerv Syst Dis; 2017; 9():1179573517728090. PubMed ID: 28855799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
    Ermer J; Corcoran M; Lasseter K; Martin PT
    Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
    Krishnan SM; Pennick M; Stark JG
    Clin Drug Investig; 2008; 28(12):745-55. PubMed ID: 18991468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
    Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
    Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine.
    Comiran E; Carlos G; Barreto F; Pechanksy F; Fröehlich PE; Limberger RP
    Biopharm Drug Dispos; 2021 Jan; 42(1):3-11. PubMed ID: 33119133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
    Krishnan S; Zhang Y
    J Clin Pharmacol; 2008 Mar; 48(3):293-302. PubMed ID: 18285619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
    Ermer J; Homolka R; Martin P; Buckwalter M; Purkayastha J; Roesch B
    J Clin Pharmacol; 2010 Sep; 50(9):1001-10. PubMed ID: 20173084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate.
    Mattingly G; Weisler R; Dirks B; Babcock T; Adeyi B; Scheckner B; Lasser R
    Innov Clin Neurosci; 2012 May; 9(5-6):22-30. PubMed ID: 22808446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate for childhood ADHD.
    Madaan V
    Drugs Today (Barc); 2008 May; 44(5):319-24. PubMed ID: 18548134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
    Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological properties and clinical effects of the ADHD drug, Lisdexamfetamine (Vyvanse
    Sakai C
    Nihon Yakurigaku Zasshi; 2020; 155(6):413-425. PubMed ID: 33132261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What place for lisdexamfetamine in children and adolescents with ADHD?
    Drug Ther Bull; 2013 Oct; 51(10):114-7. PubMed ID: 24113146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.